Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

272.58 -1.75 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,970,340
Open 275.01
Bid (Size) 272.50 (1)
Ask (Size) 273.60 (1)
Prev. Close 274.33
Today's Range 271.48 - 275.36
52wk Range 257.80 - 346.85
Shares Outstanding N/A
Dividend Yield 3.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. 
Via MarketBeat

Performance

YTD
-8.34%
-8.34%
1 Month
-15.29%
-15.29%
3 Month
-14.97%
-14.97%
6 Month
-10.64%
-10.64%
1 Year
+0.47%
+0.47%

More News

Read More
13 Healthcare Sector Stocks With Healthy Valuation
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is Amgen Still a Top Dividend Stock?
Via The Motley Fool
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
Via The Motley Fool
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Via The Motley Fool
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
Via Investor's Business Daily
Topics Government
Exposures Political
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
Via The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
Via Benzinga
Pain In Retail
Via Talk Markets
Topics Stocks / Equities
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
Via Investor's Business Daily
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
Via Benzinga
Investing in Pharma Stocks? Check These 3 Things First
Via The Motley Fool
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.